Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
3(30%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
7
70%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution7 total trials
N/ANon-phased studies
7(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(5)
Other(2)

Detailed Status

Completed5
unknown2
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A7 (100.0%)

Trials by Status

active_not_recruiting110%
completed550%
unknown220%
recruiting220%

Recent Activity

3 active trials
Showing 5 of 10
recruitingnot_applicable

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

NCT06335914
completednot_applicable

Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma

NCT04566185
recruitingnot_applicable

Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism

NCT06079294
active_not_recruitingnot_applicable

Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer

NCT02386709
completed

Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma

NCT06180213
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06335914Not Applicable

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

Recruiting
NCT04566185Not Applicable

Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma

Completed
NCT06079294Not Applicable

Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism

Recruiting
NCT02386709Not Applicable

Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer

Active Not Recruiting
NCT06180213

Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma

Completed
NCT04255628

The Brain Metabolic Change in Chronic Cancer Pain Patient: FDG PET Image Study

Unknown
NCT03212157Not Applicable

GlucoCEST MRI in Oncology

Completed
NCT04174456Not Applicable

Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy

Unknown
NCT04028804

FLT PET: A Pilot Study in Lymphoma Patients

Completed
NCT00534989Not Applicable

Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT

Completed

All 10 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
10